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Stroke is a leading cause of death and long-term disability in the industrialized countries. 
Despite advances in understanding its pathophysiology, little progress has been made in 
the treatment of stroke. The currently available therapies have proven to be highly 
unsatisfactory (except thrombolysis) and attempts are being made to identify and 
characterize signalling proteins which could be exploited to design novel therapeutic 
modalities. The peroxisome proliferators activated receptors (PPARs) are ligand-activated 
transcription factors that control lipid and glucose metabolism. PPARs regulate gene 
expression by binding with the retinoid X receptor (RXR). RXR as a heterodimeric partner 
to specific DNA sequences, termed PPAR response elements. In addition, PPARs may 
modulate gene transcription also by directly interfering with other transcription factor 
pathways in a DNA-binding independent manner. To date, three different PPAR isoforms, 
designated , / and , have been identified. Recently, they have been found to play an 
important role for the pathogenesis of various disorders of the central nervous system and 
accumulating data suggest that PPARs may serve as potential targets for treating 
ischemic stroke. Activation of all PPAR isoforms, but especially of PPAR, was shown to 
prevent post-ischemic inflammation and neuronal damage in several in vitro and in vivo 
models, negatively regulating the expression of genes induced by ischemia/reperfusion 
(I/R). This paper reviews the evidence and recent developments relating to the potential 
therapeutic effects of PPAR-agonists in the treatment of cerebral I/R injury.
Cerebral ischemia/reperfusion injury 
 
Stroke has a major impact on the public health of every nation. Ischemic stroke, which accounts for 
more than 80% of all stroke events, results from a transient or permanent reduction in cerebral 
blood flow that, in most cases, is caused by thrombotic occlusions. Ischemic damage of the central 
nervous system (CNS) may also present the clinical picture of a transient ischemic attack (TIA), 
which affords for a less severe neurological deficit in comparison with stroke. Ischemic stroke is the 
second leading cause of death in Europe and a common cause of long-term disability worldwide.  
(Frizzel, 2005). Cerebral ischemia is defined as a reduction in cerebral blood flow (CBF), sufficient 
to cause metabolic or functional deficit. The characteristics of brain injury depends on the severity 
and the duration of CBF reduction. Although reperfusion following transient ischemia leads to 
restoration of CBF, there is compelling evidence to support the notion that reperfusion may 
exacerbate the injury initially caused by ischemia, producing a so-called “cerebral 
ischemia/reperfusion (I/R) injury”. In some animal stroke models, reperfusion after a long ischemic 
period has been demonstrated to cause a larger infarct than that associated with permanent vessel 
occlusion (Aronowski et al., 1997; Yang et al., 1994). Thrombolisis, which leads to restoration of 
cerebral perfusion and at present is the only therapeutic strategy clinically used in most parts of the 
world, is not without risk (NINDS, 1995). For instance, the thrombolytic agent tissue-type 
plasminogen activator (tPA) can increase the risk of symptomatic brain hemorrhage (NINDS, 
1997), has a brief 3 h time window of efficacy, and is capable of directly causing damage to 
neurons (Nicole, 2001; Wang, 1998). Thus, while reperfusion may improve clinical outcomes in 
some patients, in others it may substantially contribute to the pathogenesis of the disease.  
The major pathogenic mechanisms of cerebral I/R injury include glutamate-mediated excitotoxicity, 
oxidative stress, inflammation, necrotic and apoptotic cell death and gene expression (Mehta et al., 
2007). These events occur in an overlapping manner and depend on the intensity and duration of the 
insult. Drugs that can interfere with one or more of these mechanisms might minimize the 
subsequent neurodegeneration, thus leading the emergence of new therapeutic interventions in 
cerebral I/R. However, in spite of the growing understanding of the mechanisms of neuronal 
damage and death accompanying brain I/R, effective therapy has remained elusive (Green and 
Shuaib, 2006). Recent discoveries portray Peroxisome Proliferator-Activated Receptors (PPARs) as 
promising pharmacological targets for the treatment of acute ischemic stroke. 
 
 
PPARs as nuclear receptors 
 
PPARs are members of the nuclear hormone receptor (NHR) superfamily of ligand-activated 
transcription factors. There are three PPAR subtypes: α, β/δ and γ, named also NR1C1, NR1C2 and 
NR1C3, respectively, according to the unified nomenclature of nuclear receptors (Nuclear 
Receptors Nomenclature Committee, 1999). The three isoforms are the products of distinct genes: 
the human PPAR- gene was mapped on chromosome 22 in the general region 22q12–q13.1, the 
PPAR- gene is located on chromosome 3 at position 3p25, whereas PPAR-/ has been assigned 
to chromosome 6, at position 6p21.1–p21.2 (Greene et al., 1995; Sher et al., 1993; Yoshikawa et al., 
1996).  PPARs were originally identified by Isseman and Green (1990) after screening the rat liver 
cDNA library with a cDNA sequence located in the highly conserved C domain of NHRs. These 
investigators demonstrated that chemicals that act as peroxisome proliferators were potent ligands 
for this new nuclear receptor, hence its designation as PPAR-. Activation of neither PPAR-β/δ nor 
PPAR-, however, elicits this response and, interestingly, the phenomenon of peroxisome 
proliferation does not occur in humans (Vamecq and Draye, 1989). The molecular basis for this 
difference between species is not yet clear. With respect to the PPAR- isotype, alternative splicing 
and promoter use results in the formation of two further isoforms: PPAR-1 and PPAR-2. In 
particular, differential promoter usage and alternate splicing of the gene generates three mRNA 
isoforms. PPAR-1 and PPAR-3 mRNA both encode the PPAR-1 protein product which is 
expressed in most tissues, whereas PPAR-2 mRNA encodes the PPAR-2 protein, which contains 
an additional 28 amino acids at the amino terminus and is specific to adipocytes (Gurnell, 2003). 
All members of this superfamily share the typical domain organization of nuclear receptors. The N-
terminal A/B domain contains a ligand-independent transactivation function. In the α and  
isotypes, the activity of this domain can be regulated by mitogen-activated protein kinase (MAPK) 
phosphorylation (Juge-Aubry et al., 1999; Hu et al., 1996). The C domain is the DNA binding 
domain with its typical two zinc-finger-like motifs, as previously described for the steroid receptors 
(Schwabe et al., 1990). The E/F domain is the ligand binding domain. It contains a ligand-
dependent trans-activation function (AF)-2 (Fajas et al., 1997), and is able to interact with 
transcriptional coactivators such as steroid receptor coactivator (SRC)- 1 (Kalkhoven et al. 1998; 
Krey et al., 1997; Onate et al., 1995) and CREB-binding protein (CBP) (Chakravarti et al., 1996; 
Dowell et al., 1997; Kamei et al., 1996).  
 
 
Endogenous and synthetic PPARs ligands 
 
A broad spectrum of natural and synthetic compounds can function as PPAR ligands by binding to 
PPARs. Although many fatty acids are capable of activating all three PPAR isoforms, some 
preference for specific fatty acids by each PPAR has been demonstrated. The long-chain 
polyunsaturated fatty acids and their oxidized derivatives, especially eicosanoids such as 8-S-
hydroxyeicosatetraenoic acid (8-S-HETE), leukotriene B4 (LTB4) and arachidonate monooxygenase 
metabolite epoxyeicosatrienoic acids have been shown to potently activate PPAR- with high 
affinity (Willson et al., 2000; Feige et al., 2006; Theocharis et al., 2004). PPAR-/ agonists 
include linoleic acid, oleic acid, arachidonic acid and eicosapentaenoic acid (EPA), which have 
been shown to co-crystallize within the ligand binding domain of this nuclear receptor (Xu et al., 
1999). A number of eicosanoids, including prostaglandin (PG) A1 and PGD2, and carbaprostacyclin, 
a semi-synthetic prostaglandin, have micromolar affinities for PPAR-/ (Forman et al., 1997). 
PPAR- can be activated by several prostanoids, such as 15-deoxy-Δ12,14-prostaglandin J2 (15d-
PGJ2) and 12- and 15-hydroxy-eicosatetraenoic acid (12- and 15-HETE), which are derivatives of 
arachidonic acid synthesized through the lipoxygenase pathway, as well as modified oxidised lipids, 
9- and 13-hydroxyoctadecadienoic acids (9- and 13-HODE) (Willson et al., 2000; Theocharis et al., 
2003; Theocharis et al., 2004). The cyclopentenone PG 15d-PGJ2 is not only the most potent 
natural ligand for PPAR- identified to date, but also by far the most commonly used naturally 
occurring PPAR- agonist (Forman et al., 1995). It was first discovered in 1983, following 
incubation of PGD2 for extended periods of time in the presence of albumin (Fitzpatrick et al., 
1983). However, it received relatively little attention until 1995 when two independent groups 
simultaneously reported that it is capable of activating PPAR- (Forman et al., 1995; Kliewer et al., 
1995).  Although it is clear that 15d-PGJ2 can stimulate PPAR-, the concentrations of 15d-PGJ2 
required to stimulate PPAR- are generally reported to be in the micromolar range (Powell, 2003). 
In addition, using a highly sensitive liquid chromatography/tandem mass spectrometry assay for 
15d-PGJ2, Bell-Parikh and colleagues reported that although 15d-PGJ2 can be generated in vivo, 
the levels produced are not sufficient to be compatible with a role for this substance as an 
endogenous ligand for PPAR- (Bell-Parikh et al., 2003). Thus, whether 15d-PGJ2 is the 
endogenous ligand for PPAR- is still not clear. Besides, it is important to note that 15d-PGJ2 can 
induce a variety of PPAR- independent responses, and 15d-PGJ2 has indeed been shown to induce 
responses in cells devoid of the receptor (Chawla et al., 2001).  
With respect to the synthetic ligands, fibrates (e.g. fenofibrate, clofibrate), which are 
hypolipidaemic drugs, are well-known ligands for PPAR- (Willson, 2000; Theocharis, 2003; 
Theocharis, 2004). Fibrates are capable are capable of activating PPAR-α at pharmacological doses 
leading to increased expression of lipid metabolizing enzymes that effectively lower serum lipid 
levels in humans. In contrast to the well-documented therapeutic effect, there is also evidence of 
liver toxicity induced by activation of PPAR-α, mainly hepatocarcinogenesis. In response to ligand 
activation by fibrates, PPAR-α mediates increased transcription of acyl-CoA oxidase and other 
target genes that lead to increased cell proliferation in the liver (reviewed in Klaunig et al., 2003; 
Peters et al., 2005). Fibrates can also interfere with aryl hydrocarbon receptor (AhR)-dependent 
signaling. Expression of the cytochrome P450 (CYP) 1A2 and enzyme activity in liver are both 
decreased in rats treated with ciprofibrate (Gallagher et al., 1995). Similarly, decreased expression 
of CYP1A1 and CYP1A2 mRNA and protein is found in rat liver after clofibrate treatment, and this 
effect appears to be due to reduced turnover of the AhR that mediates induction of CYP1A1 and 
CYP1A2 (Shaban et al., 2004). These combined observations suggest that PPAR-α ligands could 
potentially inhibit bioactivation and/or detoxification of chemical carcinogens/toxicants catalyzed 
by CYPs and, at the same time, increase cell proliferation, thus leading to hepatocellular 
carcinomas. However, clinical trials have failed to show an increase in cancer diagnoses between 
treatment groups (Keech et al., 2005; Rubins et al., 1999). The most serious safety risk associated 
with fibrates, although rare, is myopathy and rhabdomyolysis (Gaist et al., 2001). Studies suggest 
that the mechanism of myotoxicity through fibrates is not entirely clear, because complex and 
multifactorial mechanisms are involved, including genetic predisposition, pharmacokinetics, drug 
interactions, and dose. It is of interest to note that increased expression of lipoprotein lipase, which 
is known PPAR-α target gene, in skeletal muscle leads to severe myopathy in mice (Levak-Frank et 
al., 1995; Schoonjans et al., 1996).  
On the other hand, synthetic ligands for PPAR-/ are currently in preclinical phases of study: their 
safety and their therapeutic potential for obesity, dyslipidemia and type-2-diabetes is now under 
investigation in in vivo experimental models  (Takahashi et al., 2006).  
The most widely used PPAR- agonists belong to the thiazolidinedione (TZD) or glitazone class of 
anti-diabetic drugs used in the treatment of type-2 diabetes. Troglitazone, the first TZD approved 
for this use, was withdrawn from the market in March 2000 following the emergence of a serious 
hepatotoxicity in some patients. Since troglitazone induces CYP3A4 (Dimaraki and Jaffe, 2003; 
Ramachandran et al., 1999), it has been hypothesized that potentially toxic quinones derived from 
CYP3A4-dependent metabolism could cause liver damage (Neuschwander-Tetri et al., 1998; 
Yamamoto et al., 2002). The two currently available TZDs, rosiglitazone and pioglitazone, were 
approved in the United States in 1999 and are currently used alone or in combination with other oral 
anti-diabetic agents for type-2 diabetes patients (Willson et al, 2000; Theocharis et al., 2003; 
Theocharis et al., 2004; Margeli et al, 2003). On the basis of evidence from clinical trials and post-
marketing experience, rosiglitazone and pioglitazone do not appear to be associated with 
hepatotoxicity. However, there are side effects common to all TZDs, which can be deemed a class 
effect. One of the most studied toxic effects of TZDs is cardiac toxicity, mainly increased plasma 
volume leading to edema, which in turn can exacerbate congestive heart failure (Patel et al., 2005). 
This increase in fluid volume appears to be mediated by PPARγ-dependent expression of renal 
epithelial sodium channel (Guan et al., 2005b; Zhang et al., 2005). In the last few years, a large 
number of studies have revealed a broad spectrum of action for the TZD class of drugs beyond the 
treatment of diabetes, including anti-inflammatory and anti-neoplastic properties, as well as their 
critical role in atherosclerosis and various CNS diseases (Theocharis et al., 2003; Theocharis et al., 
2004; Margeli et al., 2003; Hamerman et al., 2005; Pershadsingh et al., 2004). Currently, a new 
generation of dual-action PPAR ligands, such as muraglitazar and tesaglitazar, are also being 
developed to activate both PPAR- and PPAR- in order to combine their anti-diabetic actions with 
reducing diabetic complications (Pershadsingh et al., 2006).  
 
 
Transcriptional activities of PPARs 
 
Mechanisms of transcriptional transactivation 
PPARs function as heterodimers with their obligate partner — the retinoid X receptor (RXR). Like 
other NHRs, the PPAR/RXR heterodimer probably recruits co-factor complexes — either co-
activators or co-repressors — that modulate its transcriptional activity (Surapureddi et al.,2002; 
Mueller et al., 2002; Krogsdam et al., 2002; Shi et al., 2002) The PPAR/RXR heterodimer then 
binds to sequence specific PPAR response elements (PPREs), located in the 5’-flanking region of 
target genes, thereby acting as a transcriptional regulator (Forman et al., 1995; Palmer et al., 1995; 
Varanasi et al., 1996; Zhang et al., 1996). In the absence of a ligand, to prevent PPAR/RXR binding 
to DNA, high-affinity complexes are formed between the inactive PPAR/RXR heterodimers and co-
repressor molecules, such as nuclear receptor co-repressor or silencing mediator for retinoic 
receptors. Upon binding an agonist, the conformation of a PPAR is altered and stabilized such that a 
binding cleft is created and recruitment of transcriptional co-activators occurs. The result is an 
increase in gene transcription. The search for PPAR target genes with identified PPREs has led to 
the identification of several genes involved in lipid metabolism, oxidative stress and the 
inflammatory response, as widely documented in the literature (Berger and Moller, 2002; 
Desvergne and Whali, 1000; Tan et al., 2005).  
 
Mechanisms of transcriptional transrepression. 
PPARs can also negatively regulate gene expression in a ligand-dependent manner by inhibiting the 
activities of other transcription factors, such as activated protein-1 (AP-1), nuclear factor-κB (NF-
κB), nuclear factor of activated T cells (NFAT) or signal transducer and activator of transcription 
(STAT) (ligand-dependent transrepression). In contrast to transcriptional activation, which usually 
involves the binding of PPARs to specific response elements in the promoter or enhancer regions of 
target genes, transrepression does not involve binding to typical receptor specific response elements 
(Glass et al., 2007; Pascual et al., 2006). Several lines of evidence suggest that PPARs may exert 
anti-inflammatory effects by negatively regulating the expression of pro-inflammatory genes. To 
date, several mechanisms have been suggested to account for this activity, but despite intensive 
investigation, unifying principles remain to be elucidated.  
Firstly, competition for limited amounts of essential, shared transcriptional co-activators may play a 
role in transrepression. In vitro studies have revealed a ligand type-specific direct interaction of 
PPARs with several transcriptional co-activators, such as SRC-1, TIF2, AIB-1, CBP, p300, 
TRAP220, and DRIP205 (Kodera et al., 2000). The activated PPAR/RXR heterodimer reduces the 
availability of co-activators required for gene induction by other transcriptional factors. Thus, 
without distinct co-factors, transcriptional factors cannot cause gene expression.  
Secondly, PPAR/RXR complexes may cause a functional inhibition by directly binding to 
transcription factors, preventing them from inducing gene transcription (Chung et al., 2000).  
Ligand-activated PPAR-α has been shown to interfere with DNA binding of both AP-1 and NF-κB 
activity in interleukin (IL)-1α  stimulated smooth muscle cells as measured by IL-6 induction. 
PPAR-α inhibits the vascular inflammatory response by direct protein–protein interaction with p65 
and c-Jun (Delerive et al., 1999a). Similarly, PPAR-γ inhibits lipopolysaccharide (LPS)-stimulated 
production of IL-12 in macrophages by direct interaction with p65/p50 (Chung et al., 2000). NFAT 
precipitation experiments in T cells revealed a direct contact with PPAR-, with NFAT 
sequestration accounting for suppression of T cell proliferation and activation (Yang et al., 2000). 
Both PPAR-α and PPAR-γ ligands interfere with the AP-1 signalling pathway, which mediates 
endothelin-1 (ET-1) gene expression in endothelial cells (Delerive et al., 1999b). In addition, 
PPAR-α ligands, induce the expression of the inhibitory protein inhibitor of kappa B (IκB)α in 
smooth muscle cells and hepatocytes, which sequesters the NF-κB subunits in the cytoplasm and 
consequently reduces their DNA binding activity (Delerive et al., 2000; Vanden Berghe et al., 
2003).  Zingarelli and colleagues (2003) demonstrated that PPAR-γ inhibits activation of AP-1 and 
reduces degradation of IκBα in the lungs, resulting in reduced activation of NF-κB.  
Thirdly, PPAR/RXR heterodimers may also inhibit phosphorylation and activation of several 
members of the MAPK family. In general very little is known about the molecular mechanisms by 
which PPARs and their ligands modulate kinase activities. In a study carried out in PPAR-+/- mice, 
activation of c-Jun-N-terminal kinase (JNK) and p38 in response to 2,4,6-trinitrobenzene sulfonic 
acid (TNBS)-induced colitis was significantly reduced compared with wild-type littermates 
(Desreumaux et al., 2001). Jones and colleagues (2003) have shown that unliganded PPAR-α 
suppresses the phosphorylation of p38 MAPK after T-cell stimulation. Recent studies have 
suggested another mechanism based on co-repressor-dependent transrepression by PPARs. 
Evidence has been presented in which PPAR-/ controls the inflammatory status of macrophages 
based on its association with the transcriptional repressor BCL-6 (Lee et al., 2003). In the absence 
of a ligand, PPAR-/ sequesters BCL-6 from inflammatory response genes, leading to increased 
levels of gene expression. In contrast, in the presence of ligand, PPAR-/ releases the repressor, 
which now distributes to NF-κB-dependent promoters and exerts anti-inflammatory effects by 
repressing transcription from these genes. Other studies have proposed that PPAR-γ may mediate 
transrepression of a subset of inflammatory response genes in macrophages by preventing the 
signal-dependent clearance of co-repressor complexes on inflammatory promoters downstream of 
LPS signaling (Pascual et al., 2005; Ghisletti et al, 2007). A thorough review of the mechanism of 
transcriptional transrepression of PPARs can be found in the literature (Ricote and Glass, 2007). 
 
Ligand-indipendent transrepression 
PPARs may repress the transcription of direct target genes in the absence of ligands (ligand-
independent repression). PPARs bind to response elements in the absence of ligand and recruit co-
repressor complexes that mediate active repression. The co-repressors are capable of fully 
repressing PPAR-mediated transactivation induced either by ligands or by cAMP-regulated 
signalling pathways. This suggests co-repressors as general antagonists of the various stimuli 
inducing PPAR-mediated transactivation. Co-repressors can display different ligand selectivity: the 
nuclear receptor co-repressor NCoR interacted strongly with the ligand-binding domain of PPAR-
/, whereas interactions with the ligand-binding domains of PPAR- and PPAR- were 
significantly weaker (Krogsdam et al., 2002). 
 
 
PPARs in the brain 
 
Although PPARs exhibit high homology at the amino acid level and are structurally similar, the 
tissue distribution varies greatly between the subtypes. PPAR- is found mainly in the liver, kidney, 
skeletal, and cardiac muscle, PPAR-/ is ubiquitously expressed, whereas PPAR- is mainly found 
in adipocytes and in cells of the immune system such as monocytes/ macrophages, B and T cells, 
and dendritic cells (Braissant et al., 1996; Chinetti et al., 1998; Chinetti et al., 2000; Clark et al., 
2000; Faveeuw et al., 2000; Gosset et al., 2001; Marx et al., 1998; Yang et al., 2000). Interestingly, 
all three PPAR isotypes are co-expressed in the nervous system during late rat embryogenesis. 
Their expression peaks in the central nervous system at mid-gestation. Whereas PPAR-β/δ remains 
highly expressed in this tissue, the expression of PPAR-α and PPAR-γ decreases postnatally in the 
brain (Braissant et al., 1996). While PPAR-β/δ has been found in neurons of numerous brain areas 
of adult rodents, PPAR-α and PPAR-γ have been localized to more restricted areas of the brain 
(Moreno et al., 2004; Woods et al., 2003). As shown by Moreno et al. (2004), the 
immunohistochemical localization of the three isotypes of PPARs in the CNS of the adult rat 
demonstrates that some brain areas express all the studied receptors, while others exclusively 
contain specific isotypes. The former group comprises the basal ganglia, hippocampal formation 
and many rhombencephalic nuclei; the latter includes the olfactory bulb, lacking PPAR-γ, the 
hypothalamus, immunonegative to PPAR-α and the spinal cord, generally devoid of PPAR-α. 
Besides, as reported by Kremarik-Bouillaud et al. (2000), in some regions at the distribution 
patterns are specific for the cell type. For example, in the cerebellar cortex, Golgi cells display all 
PPAR isotypes, while Purkinje cells only contain the β isotype. The localization of PPARs has also 
been investigated in purified cultures of neural cells. PPAR-β/δ is expressed in immature 
oligodendrocytes where its activation promotes differentiation, myelin maturation and turnover 
(Cimini et al., 2003; Saluja et al., 2001). The PPAR-γ isotype is the dominant isoform in microglia. 
Astrocytes possess all three PPAR isotypes, although to different degrees depending on the brain 
area and animal age (Cristiano et al., 2001; Cullingford et al., 1998). The role of PPARs in the CNS 
is mainly related to lipid metabolism; however, these receptors have been implicated in neural cell 
differentiation and death as well as in inflammation and neurodegeneration. The expression of 
PPAR-γ in the brain has been extensively studied in relation to inflammation and neurodegeneration 
(Heneka et al., 2000). PPAR-α has been suggested to be involved in acetylcholine metabolism 
(Farioli-Vecchioli et al., 2001), excitatory amino acid neurotransmission and oxidative stress 
defense (Moreno et al., 2004). PPAR-/ seems to play a critical role in regulating myelinogenesis 
and differentiation of cells within the CNS (Saluja et al., 2001; Peters et al., 2000). Several lines of 
evidence from in vitro and in vivo studies support the hypothesis that PPAR agonists could be 
potential neuroprotective drugs in neurodegenerative diseases and multiple sclerosis. These data 
have been essentially obtained with PPAR-α and PPAR-γ agonists in animal models of Alzheimer’s 
disease, Parkinson disease and experimental allergic encephalitis, an established animal model of 
multiple sclerosis (Feinstein, 2003). 
 
 
PPARs and cerebral ischemia/reperfusion injury 
 
Experimental models of cerebral I/R injury 
Although the relevance of animal models to the development of therapies for acute stroke has been 
often questioned, evidence demonstrates that animal models of stroke do have clinical relevance 
and are useful in the development of drugs that attenuate I/R-induced damage (Green et al., 2003). 
A role for PPARs in reducing I/R injury has been first established in animal models of acute 
myocardial infarction (Yue et al., 2001; Wayman et al., 2002). More recently, good evidence 
supporting the beneficial effects of PPAR agonists in stroke has been provided by several in vivo 
experimental models of cerebral I/R injury. It has been demonstrated that a 14-day preventive 
treatment with fenofibrate reduced susceptibility to stroke in apolipoprotein E-deficient mice as 
well as decreased cerebral infarct volume in wild-type littermates (Deplanque et al., 2003). The 
authors demonstrated that fenofibrate administration was associated with a decrease in cerebral 
oxidative stress depending on the increase in activity of several anti-oxidant enzymes and with a 
reduced expression of adhesion molecules. In another study, it was confirmed that two different 
PPAR- agonists, fenofibrate and WY14643, provided similar brain protection when administered 
3 or 7 days, respectively, before the induction of cerebral ischemia (Inoue et al., 2003). More 
recently, we have found that PPAR- agonists may also reduce cerebral I/R injury when 
administered just before ischemia or during reperfusion (Collino et al., 2006a). Specifically, we 
reported that administration of the selective PPAR- agonist, WY14643 decreased reactive oxygen 
species (ROS) production and lipid peroxidation in the hippocampus of rats subjected to I/R and, at 
the same time, offered protection from I/R-induced inducible nitric oxide synthase (iNOS) and 
intercellular adhesion molecule-1 (ICAM-1) overexpression. We showed that the potential 
neuroprotective effects of PPAR- agonists is manifested by modulation of protein S100B levels in 
the rat CNS. S100B is a calcium-binding protein, mainly expressed in the brain and recent clinical 
studies indicate that increased S100B levels is a reliable indicator of infarct size in patients with 
stroke (Buyukuysal, 2005). Pre-treatment of rats with the selective PPAR- agonist, WY14643, 
prior to cerebral ischemia causes a marked reduction of S100B levels in the rat hippocampus 
(Figure 1). This protective effect is reversed by administration of the PPAR- antagonist, MK886, 
thus confirming the involvment of PPAR- activation in neuroprotection. The key role of PPAR- 
isotype after focal cerebral ischemia has been further demonstrated by using PPAR--/- mice (Pialat 
et al., 2007). However, the principal focus of studies of PPAR agonists has been on agonists of the 
PPAR-γ isoform. Emerging studies have reported the protective effects of PPAR- agonist 
administration in animal models of cerebral I/R injury (Allahtavakoli et al., 2007; Allahtavakoli et 
al., 2006; Shimazu et al., 2005; Sundararajan et al., 2005; Collino et al., 2006b). These 
neuroprotective effects have been related to the inhibition of I/R-induced inflammatory markers 
(IL-1 β, iNOS, ICAM-1, cyclooxygenase-2 [COX-2]) and to an anti-oxidant effect (increased 
expression of superoxide dismutase 1, reduced production of ROS, lipid peroxidation and 
glutathione [GSH] depletion). In one of these studies, infarct volume was reduced and neurological 
function was improved by PPAR- agonist treatment when measured 22 days after the ischemic 
event. This suggests that agonist treatment near the time of ischemia, has long term protective 
effects (Sundararajan et al., 2005). The relevance of PPAR-γ as an endogenous protective factor 
was also shown by the fact that treatment with a PPAR-γ antagonist increased infarct size (Victor et 
al., 2006). The intracerebroventricular application of the PPAR-γ agonist pioglitazone has been 
demonstrated as effective as systemic application, thus indicating that the protection is brought 
about by the selective stimulation of intracerebral PPAR-γ (Zhao et al., 2005). PPAR-γ mRNA is 
up-regulated in ischemic brain, especially in the peri-infarct area. Increased PPAR-γ mRNA was 
detected in the infarcted brain as early as 6 h following focal ischemia (Ou et al., 2006), and PPAR-
γ immunopositive neurons were detected between 4 h and 14 days (Victor et al., 2006), whereas in 
neurons and microglia only transiently at 12 h in the post-ischemic brain (Zhao et al., 2006a and 
Zhao et al., 2006b). Surprisingly, the increased neuronal PPAR-γ expression was associated with a 
reduced DNA-binding activity. As reported by Victor and colleagues (2006) ischemia reduced 
PPAR-γ binding in the ipsilateral hemisphere of the brain, and rosiglitazone treatment increased the 
binding in general, where it resulted in a more noticeable increase in binding activity on the 
contralateral side to the injury. Similarly, administration of the natural PPAR-γ ligand, 15d-PGJ2, 
resulted in increased binding of PPAR-γ to the PPRE and reduced the area of infarct (Ou et al., 
2006). 
Recently, the beneficial role of PPAR-β/δ in stroke has been demonstrated by two different studies 
in which PPAR-β/δ-/- mice subjected to cerebral I/R showed significantly larger infarct size than 
wild-type littermates (Arsenijevic et al., 2006; Pialat et al., 2007). This finding is confirmed by 
another study demonstrating that intracerebroventricular administration of high affinity PPAR-β/δ 
agonists such as L-165041 and GW501516 significantly decreased the infarct volume at 24 h of 
reperfusion after cerebral ischemia in rats (Iwashita et al., 2007).  
 Clinical evidence 
As already mentioned, pioglitazone and rosiglitazone (TZD class of PPAR- agonists) have proven 
to be beneficial in type-2 diabetes mellitus patients. Diabetics are at an increased risk of stroke 
incidence and stroke causes more damage in diabetics compared to normoglycemic individuals 
(Kagansky et al., 2001).  The outcome of a large clinical trial (PROactive) has recently been 
reported and demonstrated that pioglitazone significantly reduces the combined risk of heart 
attacks, strokes and death by 16% in high risk patients with type-2 diabetes (Dormandy et al., 
2005). However, TZDs are hampered by adverse effects related to increased weight gain, fluid 
overload, and congestive heart failure, so their role in prevention of cardiovascular diseases is not 
yet fully defined. Recently, enhanced functional recovery was reported in a small group of stroke 
patients with type-2 diabetes treated with pioglitazone or rosiglitazone (Lee and Reding, 2006). 
Importantly, high plasma levels of 15d-PGJ2 (the natural ligand for PPAR-) have been associated 
with good neurological outcome and smaller infarct volume in patients with an acute 
atherothrombotic stroke (Blanco et al., 2005). Moreover, a recent report suggests that the Pro12Ala 
polymorphism of PPAR-γ2 is associated with a reduced risk for ischemic stroke (Lee et al., 2006), 
further supporting the importance of PPARs in cerebral ischemia.  
Abnormal levels of serum lipids, including triglycerides, low density lipoprotein (LDL) and high 
density lipoprotein (HDL), are regarded as other important risk factors for cerebrovascular disease, 
including stroke. The association between hypercholesterolemia and stroke has become more 
apparent because of data from prospective cohort studies that show higher risks of ischemic stroke 
with increasing levels of total cholesterol in both men and women (Iso et al., 1989; Kagan et al., 
1980; Leppala et al., 1999; Horenstein et al., 2002). Increased HDL cholesterol levels have a 
protective effect against the occurrence of ischemic stroke (Soyama et al., 2003; Sacco et al., 2001) 
and elevated triglyceride levels have also been reported as a risk factor for stroke (Horenstein et al., 
2002; Tanne et al., 2001). Overall, elevated total cholesterol confers an approximately two-fold 
relative increase in stroke risk for men and women (Goldstein et al., 2001). As fibrates are used as 
lipid-lowering agents, it has been supposed that these PPAR- agonists could also protect the brain 
against noxious biological reactions induced by cerebral ischemia/reperfusion (I/R). A very recent 
systematic meta-analysis of randomized clinical trials shows that fibrates do not significantly 
reduce the odds of stroke (Saha et al., 2007). However, data from large trials specifically 
investigating the role of fibrates in stroke event reduction are needed to conclusively elucidate their 
potential neuroprotective role. For instance, a large clinical trial, named Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) is currently testing the ability of fenofibrate to 
decrease stroke incidence in high-risk patients with type-2 diabetes (ACCORD study group 2007).  
 
 
Mechanisms of beneficial effects of PPARs against cerebral ischemia/reperfusion injury 
 
Cerebral I/R is known to induce generation of ROS, as well as the expression of cytokines, 
adhesion molecules and enzymes involved in the inflammatory response, and is known to be 
regulated  by oxygen- or redox-sensitive mechanisms (Dirnagl et al., 1999). Recent studies have 
confirmed the pivotal role of both oxidative stress and inflammatory response in the pathogenesis of 
acute ischemic stroke (del Zoppo, 2006; Schaller 2005). Through various mechanisms PPARs can 
regulate both inflammatory and oxidative pathways and PPAR agonist-induced neuroprotection 
seems to be specific for injuries in which inflammation or free radical generation are the main 
causes of cell damage. For instance, PPAR- activation can induce expression and activation of 
antioxidant enzymes, such as superoxide dismutase (SOD) and glutathione peroxidase (GSH). We 
have demonstrated that administration of a highly selective PPAR- agonist, WY14643, 30 min 
prior to I/R, decreased ROS production and lipid peroxidation in rats subjected to I/R and, at the 
same time, offered protection against GSH depletion (Collino et al., 2006a). Similar results on 
oxidative stress modulation have been reported when another PPAR- agonist, fenofibrate, was 
tested in a mouse model of middle cerebral artery occlusion (Deplanque et al., 2003). Interestingly, 
PPAR--/- mice have been found to exhibit significant increases in oxidative stress and lipid 
peroxidation much earlier in their life than wild-type littermates (Poynter, et al., 1998). The PPAR-
induced protective effect on oxidative stress could be related to a direct effect on antioxidant 
enzyme expression, as the catalase and SOD gene promoters contain the PPRE (Moraes et al., 2006, 
Girnum et al., 2002; Hwang et al., 2005). In fact, rats that have been treated with a diet containing 
PPAR- ligands, WY14,643 or fenofibrate, have demonstrated an enhanced expression of 
antioxidant enzymes such as SOD and catalase (Toyama et al., 2004). Based on gene expression 
microarray experiments, Coleman and colleagues (2007) demonstrated that PPAR-β/δ activation 
increased mRNA for aldheyde dehydrogenase and glutathione-S-transferase, thus protecting the cell 
from oxidative damage. In normotensive and hypertensive animals treated with rosiglitazone, 
ischemic hemispheres showed increased catalase and Cu/Zn-SOD activity in the peri-infarct region 
(Tureyen et al., 2007) and the level of Cu/Zn-SOD was demonstrated to increase in the ischemic 
cortex of animals treated with pioglitazone for 4 days prior to focal cerebral ischemia (Shimazu et 
al., 2005). As we have recently shown, treatment of rats with either pioglitazone or rosiglitazone 
before occlusion of the common carotid artery decreased the production of ROS and nitrite, 
decreased lipid peroxidation and reversed the depleted stores of glutathione in the hippocampus 
(Collino et al., 2006b). These findings are supported by data from an in vitro model demonstrating 
that pre-treatment with PPAR-γ agonists protected an immortalized mouse hippocampal cell line 
against oxidative stress induced by glutamate or hydrogen peroxide (Aoun et al. 2003). Moreover, 
PPAR-γ agonists attenuate the expression of iNOS in inflammatory cells (Sundararajan et al., 2995; 
Pereira et al., 2005), which is an important source of nitric oxide (NO). NO may react with ROS to 
produce peroxynitrites, with deleterious effects on neuronal survival. Thus, iNOS inhibition may 
represent a further mechanism for neuroprotection by PPAR agonists. Mitochondria are the major 
source of ROS, which are mainly generated at complexes I and III of the respiratory chain (Kudin et 
al., 2005). There is now evidence indicating that rosiglitazone and pioglitazone exert direct and 
rapid effects on mitochondrial respiration, inhibiting complex I (Brunmair et al., 2004) and complex 
III (Dello Russo et al., 2003) activity. As PPAR-γ agonists partially disrupt the mitochondrial 
respiratory chain, both electron transport and superoxide anion generation are affected. Moreover, a 
novel mitochondrial target protein for PPAR-γ agonists (“mitoNEET”) has recently been identified 
(Colca et al., 2004). MitoNEET was found associated with components of complex III, suggesting 
how binding of PPAR-γ agonists to mitoNEET could selectively block different mitochondrial 
targets. The ability of PPAR-γ agonists to influence mitochondrial function might contribute to their 
inhibitory effects on ROS generation evoked by I/R. 
Another mechanism through which PPAR agonists may provide neuroprotection is by down-
regulating inflammatory response associated with I/R. Depending on the affected tissue and which 
PPAR isoforms are involved, PPAR agonists can differently modulate the intensity, duration and 
consequences of inflammatory events. For instance, ischemia-induced COX-2 overexpression is 
prevented by PPAR- agonists but not by PPAR- agonists (Zhao et al., 2006b; Collino et al., 
2006a; Sundararajan et al., 2005; Collino et al., 2006b). Activation of PPAR-γ attenuates the 
expression of matrix metalloproteinase (MMP)-9 and various inflammatory cytokines in ischemic 
brain tissue (Luo et al., 2006; Pereira et al., 2005). PPAR- is constitutively expressed in 
macrophages and microglial cells (Bernardo et al., 2000) and the systemic treatment of rodents with 
rosiglitazone reduces the infiltration of these cells into peri-infarct brain regions (Luo et al., 2006; 
Sundararajan et al., 2005).  Both chronic and acute administration of PPAR- agonists has been 
demonstrated to prevent cerebral I/R-induced expression of vascular cell adhesion molecule-1 
(VCAM-1) and ICAM-1 in two independent studies (Deplanque et al. 2003; Collino et al., 2006a). 
In the brain, the decreased expression of these adhesion molecules might contribute to inhibit the 
infiltration of the brain ischemic area by neutrophils (Lee et al., 2000; Chan, 2001).  
Studies addressing the molecular mechanisms of these anti-inflammatory actions demonstrated that 
the involvement of PPARs in the control of I/R-induced inflammation is mediated mainly through 
their transrepression capabilities. PPARs can suppress the activities of many distinct families of 
transcription factors. The range of transcription factors affected and the mechanisms involved may 
be different for each PPAR isotype, although a common mechanism of PPAR- and PPAR- 
neuroprotection  appears to involve, inhibition of p38 MAPK activation and NF-κB, nuclear 
translocation (Figure 2). A recent study confirmes that PPAR- activation prevents the post-
ischemic cerebral expression of pro-inflammatory transcription factors, such as Egr1, C/EBP and 
NF-κB, possibly by decreasing DNA binding (Tureyen et al., 2007). The inhibitory protein IκB, 
which is an indicator of NF-κB transcriptional activity, is remarkably increased in the brain of rats 
that underwent cerebral ischemia and completely blocked by rosiglitazone and 15d-PGJ2 
administration, thus further confirming that both endogenous and synthetic PPAR- ligands inhibit 
NF-κB signalling (Pereira et al., 2006). Similarly, p38 MAPK and NF-κB activation by cerebral I/R 
has been demonstrated to be inhibited by pre-treatment with the PPAR- agonist WY14643 or the 
PPAR- agonist pioglitazone (Figure 2). However, as MAPK and NF-κB are functionally 
interconnected and do not act independently (Carter et al., 1999; Vanden Berghe et al., 1998), we 
cannot rule out the possibility that PPARs affect NF-κB activation by interfering with the MAPK 
signalling cascade or vice versa (Figure 3).  
The generation of ROS is known to be associated with the induction of apoptosis and, in neurons, 
inhibition of cell death is an important factor to prevent I/R injury. PPAR activation may decrease 
the I/R-induced activation of apoptotic pathways depending on the increase in activity and 
expression of numerous anti-oxidant enzymes. Moreover, by their anti-inflammatory action on 
miocroglia and astrocytes, PPAR agonists prevent the release of neurotoxic agents, which induce 
neuronal apoptosis (Combs et al., 2000).  For instance, pioglitazone prevented ischemia-induced 
increase in pro-apoptotic Bax, while increasing anti-apoptotic Bcl-2 expression in the peri-infarct 
area following focal ischemia (Sakamoto et al., 2000; Sulejczak et al., 2004). Chu and colleagues 
(2006) showed that rosiglitazone-fed rats had better neurological scores and reduced number of 
TUNEL-positive cells following transient focal ischemia. Interestingly, these authors also reported 
an increased vasculature in the rosiglitazone-treated group with increased number of endothelial 
cells positive for BrdU, suggesting there may be enhanced angiogenesis following PPAR- 
activation. Administration of a selective PPAR- agonist (L-796449) 10 min prior to permanent 
cerebral artery occlusion, resulted in decreased apoptosis, measured as reduction of caspase-3 
activity (Pereira et al., 2005). Another study confirmed inhibition on caspase-3 activity by both 
exogenous and endogenous PPAR- agonists, rosiglitazone and 15d-PGJ2, in the ischemic cortex 
(Lin et al., 2006). The same authors observed that rosiglitazone and 15d-PGJ2 exhibit a 
concentration-dependent paradoxical effect on cytotoxicity, when tested in an in vitro model of 
hydrogen peroxide induced neuronal apoptosis. The drugs induced pro-apoptotic effects when used 
at concentrations higher that 5 mol/L but protect neurons from necrosis and apoptosis at 
concentrations lower than 1 mol/L. The reason for this paradoxical action is unclear and further 
studies are needed to better clarify the effects of PPARs in I/R induced-apoptosis and necrosis. 
Recently published data suggest that an increased uptake of cerebral extracellular glutamate levels 
after ischemia may represent an additional mechanism for the neuroprotection exerted by PPAR- 
activation (Romera et al., 2007). Both in vivo and in vitro experiments showed that rosiglitazone 
administration increased the expression of the GLT1/EAAT2 glutamate transporter in the brain, 





Although clinical data are limited, a wide array of evidence obtained in animal models now shows 
that PPAR activation may be a rational and effective strategy against ischemic brain damage. The 
beneficial effects of PPAR agonists in experimental models of stroke are mediated by different 
mechanisms, as expected based on their pleiotropic pharmacological profile. The neuroprotective 
actions appear to be mainly related to the reduction in oxidative damage as well as anti-
inflammatory and anti-apoptotic effects (Figure 3). These results have been essentially obtained 
with PPAR- and PPAR- agonists, while the PPAR-/ pathway remains largely unexplored, 
despite a significant interest in this target. Selective activation of different isoforms of PPARs may 
account for the difference in molecular pathways underlying neuroprotection and these different 
features still remain far from being completely understood. In conclusion, currently available 
management protocols for patients with stroke may benefit from the use of PPAR agonists that 
target detrimental processes associated with I/R injury. However, critical issues still wait to be 
resolved. For instance, well-structured clinical trials aimed to evaluate the effects of PPAR ligands 
on stroke recovery are needed before firm conclusions are drawn about their therapeutic efficacy. A 
more stringent approach regarding the concentration range of PPAR agonists, especially within the 
CNS, and the duration of exposure should be applied. Also acceptable water solubility with 
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Figures Legend 
 
Figure 1 The PPAR- agonist WY14643 protects against the I/R-induced overexpression of 
S100B, a calcium binding protein, which has been recognized as marker of neuronal damage. Rats 
were administered 6 mg/kg WY 14643 (I/R + WY14643) 30 min prior to cerebral I/R. A group of 
rats was pretreated with both the selective PPAR- antagonist MK886 (6 mg/kg) and the PPAR- 
agonist WY14643 WY14643 (6 mg/kg) before I/R (I/R + WY14643 + MK886). Protein levels were 
detected in the rat hippocampus homogenates after 30 min ischemia followed by 6 h reperfusion 
(Panel A). Densitometric analysis of the related bands is expressed as relative optical density (O.D.) 
of the bands, corrected for the corresponding -actin contents and normalised using the related 
sham-operated band (Panel B). Densitometry results are expressed as means  S.E.M. of three 




Figure 2 Effect of pre-treatment with the PPAR- agonist, WY14643, and the PPAR- agonist, 
pioglitazone, on phosphorylation of p38 MAPK (Panel A) and nuclear translocation of p65 NF-B 
(Panel B) evoked by cerebral I/R injury. Phosphorylated p38 MAPK was detected at 1, h 
reperfusion in rat hippocampus homogenates. NF-B translocation from the cytosol to the nucleus 
was evaluated at the same reperfusion time, measuring NF-B p65 subunit levels in both cytosol 
and nuclear fractions and expressing the results as nucleus/cytosol ratio (Panel B). Rats were 
administered 6 mg/kg WY14643 (I/R+WY14643) or 1 mg/kg pioglitazone (I/R+Pioglitazone) 
before 30 min ischemia. Densitometric analysis of the related bands is expressed as relative optical 
density (O.D.) of the bands, corrected for the corresponding -actin contents and normalised using 
the related sham-operated band. Densitometry results are expressed as means  S.E.M. of three 
separate experiments. Statistical analysis:  p < 0.01 versus I/R. (Modified from Collino et al., 
2006a and Collino et al., 2006b) 
 
 
Figure 3 Multiple targets for PPARs in cerebral I/R-induced injury. The tissue injury associated 
with cerebral I/R results in the activation of MAPKs and transcription factors (including NF-kB, 
AP-1, STAT, NFAT). The stimulation of PPARs by selective agonists in brain tissues evokes 
multiple effects that result in regulation of the MAPK cascade and inhibition of transcription factors 
activation (Figure 3a). As shown in Figure 3b, PPARs activation may cause a functional inhibition 
of proteins of the NF-kB family, such as p50 and p65, thus preventing them from inducing the 
transcription of genes involved in the oxidative stress pathway and in the inflammatory and 
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